Pacific Biosciences Of California (PACB) Revenue Growth (3y) (2013 - 2026)
Pacific Biosciences Of California (PACB) Revenue Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 202.72 Bn | 197.12 Bn | 7.27 Bn | 8.07% |
| 2 | Stryker | 126.42 Bn | 122.94 Bn | 4.50 Bn | 9.66% |
| 3 | Medtronic | 119.75 Bn | 110.53 Bn | 6.41 Bn | 4.70% |
| 4 | Boston Scientific | 74.13 Bn | 73.60 Bn | 3.85 Bn | 14.78% |
| 5 | Edwards Lifesciences | 51.78 Bn | 47.53 Bn | 1.35 Bn | 10.83% |
| 6 | Dexcom | 35.29 Bn | 33.34 Bn | 830.00 Mn | 14.51% |
| 7 | GE HealthCare Technologies | 33.95 Bn | 31.85 Bn | 2.18 Bn | 3.20% |
| 8 | Koninklijke Philips | 26.22 Bn | 22.90 Bn | 4.55 Bn | 25.44% |
| 9 | Steris | 23.21 Bn | 22.73 Bn | 684.20 Mn | 8.05% |
| 10 | Pacific Biosciences Of California | 419.38 Mn | 182.51 Mn | 12.64 Mn | -6.40% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -6.40% |
| Mar 31, 2026 | -1.50% |
| Dec 31, 2025 | 17.74% |
| Sep 30, 2025 | 5.96% |
| Jun 30, 2025 | 3.89% |
| Mar 31, 2025 | 3.85% |
| Dec 31, 2024 | 2.88% |
| Jun 30, 2024 | 5.57% |
| Mar 31, 2024 | 10.20% |
| Dec 31, 2023 | 29.08% |
| Sep 30, 2023 | 42.91% |
| Jun 30, 2023 | 40.71% |
| Mar 31, 2023 | 35.61% |
| Dec 31, 2022 | -0.69% |
| Sep 30, 2022 | 13.82% |
| Jun 30, 2022 | 12.94% |
| Mar 31, 2022 | 26.40% |
| Dec 31, 2021 | 22.64% |
| Jun 30, 2021 | 12.36% |
| Mar 31, 2021 | 14.41% |